Gastric & Stomach Cancer Treatment in India for International Patients: 2026 Guide
Priya Sharma
Oncology & Cancer Care Writer
Gastric & Stomach Cancer Treatment in India for International Patients: 2026 Guide
Gastric cancer — cancer of the stomach — is the fifth most common cancer globally and kills more than 760,000 people each year. In Africa, gastric cancer is particularly prevalent in the eastern and southern regions, driven primarily by the extremely high prevalence of Helicobacter pylori (H. pylori) infection across the continent. H. pylori, a bacterium that colonises the stomach lining, is the single most important risk factor for gastric adenocarcinoma and infects an estimated 70–80% of adults in sub-Saharan Africa.
The challenge is diagnosis. Gastric cancer typically causes no symptoms in its early stages, and most African patients present with locally advanced disease when standard treatment — surgery, chemotherapy, and targeted therapy — still offers meaningful survival benefit. India's surgical oncology centres are equipped to manage all stages of gastric cancer with internationally benchmarked protocols, at costs that are 60–75% below Western pricing.
Cost summary: Gastrectomy (stomach cancer surgery) in India costs $12,000–20,000 depending on extent and approach. Perioperative FLOT chemotherapy adds $5,000–14,000. HIPEC for selected peritoneal disease is available at specialist centres. In the USA, comparable treatment costs $60,000–150,000.
H. Pylori and Gastric Cancer in Africa
The Africa-gastric cancer story is essentially an H. pylori story. H. pylori infects the stomach lining, causes chronic gastritis, which progresses over decades through atrophic gastritis, intestinal metaplasia, and dysplasia to adenocarcinoma in a minority of infected individuals.
Crucially, H. pylori is curable. Seven-to-fourteen day antibiotic regimens (triple or quadruple therapy including a proton pump inhibitor, clarithromycin, amoxicillin, and/or metronidazole) eradicate the bacteria in 85–90% of patients. Successful eradication reduces the subsequent risk of gastric cancer.
For patients with a new gastric cancer diagnosis: H. pylori status should be tested and any active infection treated as part of overall management.
For family members of gastric cancer patients: H. pylori testing and eradication in first-degree relatives is strongly recommended, as both H. pylori infection and gastric cancer risk cluster in families.
Staging Gastric Cancer: The Foundation of Treatment Planning
Accurate staging is essential before any treatment decision. The TNM staging system describes:
- T stage: Depth of tumour invasion (T1 = confined to the innermost layers; T4b = invading adjacent organs)
- N stage: Regional lymph node involvement (N0 = none; N3b = ≥16 nodes involved)
- M stage: Distant metastasis (M0 = none; M1 = present)
Staging Investigations in India
On arrival in India with a new or recent gastric cancer diagnosis, the team will complete the following within two to three days:
Endoscopic ultrasound (EUS): The single most accurate test for T and N staging of gastric cancer. An ultrasound probe on the end of an endoscope assesses the depth of tumour penetration through the stomach wall layers and evaluates perigastric lymph nodes. Essential for deciding whether endoscopic resection (for T1a) or surgical resection is appropriate.
CT scan of chest, abdomen, and pelvis: For assessment of lymph node spread and distant metastasis.
Diagnostic laparoscopy: For tumours that appear locally advanced on imaging, a keyhole examination of the abdominal cavity identifies occult peritoneal spread (tiny tumour deposits on the peritoneal surface) not visible on CT. This is critical — up to 30% of apparently resectable gastric cancers have occult peritoneal metastases visible at laparoscopy. If peritoneal spread is found, the treatment plan shifts from curative surgery to palliative systemic treatment.
Molecular testing: HER2 (human epidermal growth factor receptor 2) status by immunohistochemistry and FISH on the biopsy specimen. HER2-positive gastric cancer (approximately 15–20% of cases) is treated differently, with trastuzumab added to first-line chemotherapy. MSI (microsatellite instability) and PD-L1 testing guide immunotherapy eligibility.
Surgical Treatment: Gastrectomy for Gastric Cancer
Surgery is the only curative treatment for non-metastatic gastric cancer. The goal is complete tumour removal (R0 resection — no cancer cells at the margins) with adequate D2 lymphadenectomy.
Types of Gastrectomy
Distal gastrectomy (partial stomach removal): For cancers of the lower two-thirds of the stomach (antrum, body). The lower two-thirds of the stomach is removed and the remaining stomach is reconnected to the small intestine. The patient retains a functional stomach remnant.
Total gastrectomy: For cancers of the upper stomach, the gastro-oesophageal junction, or diffuse-type (signet ring cell) cancers involving multiple areas. The entire stomach is removed and the oesophagus is connected directly to the small intestine (Roux-en-Y oesophagojejunostomy). Nutritional consequences are greater — lifelong vitamin B12 injections, iron, and other supplementation are required.
Proximal gastrectomy with double-tract reconstruction: For selected early-stage tumours of the upper stomach, this function-preserving technique is increasingly used at expert centres.
D2 Lymphadenectomy: The Indian Standard
D2 lymphadenectomy — systematic removal of at least 16 regional lymph nodes along specific anatomical stations around the stomach (stations 1–12 for total gastrectomy) — is the internationally recognised standard for curative gastric cancer surgery. The DUTCH trial demonstrated a 15% improvement in ten-year overall survival for D2 versus D1 dissection.
All major Indian GI oncology centres perform D2 lymphadenectomy as the routine standard. Your surgeon will document the lymph node harvest count in the operative report — the minimum acceptable is 15 nodes for adequate staging.
Laparoscopic and Robotic Gastrectomy
Laparoscopic gastrectomy: Three to five small incisions allow placement of camera and instruments. The surgeon operates using a video display. Advantages include reduced post-operative pain, smaller scars, shorter hospital stay, and faster return to normal activity.
Robotic-assisted gastrectomy (Da Vinci system): Robotic instruments offer greater precision in confined spaces, better depth perception, and improved ergonomics for the complex D2 dissection. Available at Apollo, Max, Medanta, Kokilaben, and Manipal Hospitals.
Cost of Gastrectomy in India
| Procedure | India | USA | UK Private |
|---|---|---|---|
| Distal gastrectomy (laparoscopic) | $12,000–16,000 | $40,000–80,000 | $25,000–45,000 |
| Total gastrectomy (laparoscopic) | $15,000–20,000 | $50,000–100,000 | $30,000–55,000 |
| Robotic gastrectomy | $18,000–25,000 | $60,000–110,000 | $35,000–65,000 |
Perioperative Chemotherapy: The FLOT Regimen
For Stage II and III resectable gastric cancer, international guidelines recommend perioperative chemotherapy — chemotherapy given both before and after surgery. The current standard regimen is FLOT:
- F — Fluorouracil (5-FU)
- L — Leucovorin (folinic acid)
- O — Oxaliplatin
- T — Docetaxel (Taxotere)
Four cycles are given before surgery (approximately eight weeks), and four cycles after surgery. The FLOT4 trial demonstrated superior overall survival for FLOT versus the older ECF/ECX regimens.
Pre-operative chemotherapy aims to:
- Shrink the primary tumour (downstaging), making surgery technically easier and increasing the chance of clear margins
- Treat micrometastatic disease that may be present but not yet visible on imaging
- Test the tumour's chemosensitivity — good response predicts better prognosis
Cost of FLOT chemotherapy in India: $600–1,200 per cycle. Full eight-cycle perioperative course: $5,000–10,000.
HIPEC: Hyperthermic Intraperitoneal Chemotherapy
HIPEC is a specialised treatment used in carefully selected patients with limited peritoneal disease from gastric cancer. After surgically removing all visible tumour (cytoreductive surgery), heated chemotherapy (typically cisplatin and mitomycin) is circulated within the abdominal cavity for 90 minutes. The heat enhances chemotherapy penetration and kills residual microscopic tumour cells.
HIPEC for gastric cancer is not appropriate for all patients — it requires:
- Complete or near-complete cytoreduction (peritoneal cancer index score ≤6)
- No systemic (liver, lung, bone) metastases
- Good performance status and fitness for major surgery
Centres offering HIPEC for gastric cancer in India include Tata Memorial Mumbai, Apollo Cancer Centre Delhi, and Max Cancer Centre Delhi.
Cost of HIPEC + cytoreductive surgery in India: $18,000–30,000.
Targeted Therapy and Immunotherapy
HER2-Positive Gastric Cancer (first-line): Trastuzumab (Herceptin) added to FOLFOX or capecitabine-cisplatin chemotherapy (ToGA regimen) is the standard first-line treatment for HER2-positive (IHC3+ or IHC2+/FISH+) advanced gastric cancer. Trastuzumab biosimilars are available in India at significantly reduced cost compared to originator pricing.
Pembrolizumab (Keytruda): The KEYNOTE-590 and KEYNOTE-811 data support pembrolizumab addition to chemotherapy for PD-L1-positive gastric cancer in the first-line setting. India has access to pembrolizumab, with biosimilar alternatives emerging.
Ramucirumab (Cyramza): Anti-VEGFR2 antibody for second-line treatment of advanced gastric cancer, available at major Indian oncology centres.
Nutrition After Gastrectomy
Nutritional management is a critical — and often underemphasised — element of gastric cancer treatment. After gastrectomy:
Short-term: Fluids only initially, progressing to soft foods over two weeks. Dumping syndrome (sweating, palpitations, diarrhoea after meals) is common after distal gastrectomy, managed by eating small, frequent, low-sugar meals.
Long-term after total gastrectomy: Vitamin B12 injections (monthly, lifelong), iron supplements, calcium and vitamin D, fat-soluble vitamins. Regular nutritional monitoring. Weight loss of 10–15% in the first six months is common and expected.
India's oncology dietitians provide detailed post-gastrectomy dietary plans and can guide families on specific preparation of appropriate foods.
Planning Your Gastric Cancer Treatment in India
Step 1: Share endoscopy and biopsy reports, CT scans, and blood tests with Arodya. A GI oncologist reviews within 48–72 hours.
Step 2: Receive a treatment plan outline and cost estimate before travelling.
Step 3: Travel to India for staging completion, multidisciplinary tumour board review, and treatment.
Step 4: Surgery, perioperative chemotherapy (or chemotherapy alone), and targeted therapy coordinated in India. Some chemotherapy cycles can continue at home.
To request a case review for gastric cancer treatment in India, start your enquiry with Arodya. India's gastric cancer surgical oncology teams have the experience, the protocols, and the infrastructure to give you the best possible chance at cure.
For a comparison of cancer treatment costs between India and Western countries, see our cancer treatment cost guide.
